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Abstract
Background: Non-optimal blood pressure (BP) levels are a major cause of disease burden globally. We describe
current BP and treatment patterns in rural India and compare different approaches to BP lowering in this setting.
Methods: All individuals aged ≥40 years from 54 villages in a South Indian district were invited and 62,194
individuals (84%) participated in a cross-sectional study. Individual 10-year absolute cardiovascular disease
(CVD) risk was estimated using WHO/ISH charts. Using known effects of treatment, proportions of events that would be
averted under different paradigms of BP lowering therapy were estimated.
Results: After imputation of pre-treatment BP levels for participants on existing treatment, 76·9% (95% confidence
interval, 75.7–78.0%), 5·3% (4.9–5.6%), and 17·8% (16.9–18.8%) of individuals had a 10-year CVD risk defined as low
(< 20%), intermediate (20–29%), and high (≥30%, established CVD, or BP > 160/100 mmHg), respectively. Compared to
the 19.6% (18.4–20.9%) of adults treated with current practice, a slightly higher or similar proportion would be
treated using an intermediate (23·2% (22.0–24.3%)) or high (17·9% (16.9–18.8%) risk threshold for instituting BP
lowering therapy and this would avert 87·2% (85.8–88.5%) and 62·7% (60.7–64.6%) more CVD events over ten
years, respectively. These strategies were highly cost-effective relative to the current practice.
Conclusion: In a rural Indian community, a substantial proportion of the population has elevated CVD risk. The
more efficient and cost-effective clinical approach to BP lowering is to base treatment decisions on an estimate
of an individual’s short-term absolute CVD risk rather than with BP based strategy.
Clinical trial registration: Clinical Trials Registry of India CTRI/2013/06/003753, 14 June 2013.
Keywords: Cardiovascular disease, Absolute risk, India, Treatment, Blood pressure
Background
Cardiovascular diseases (CVD) are a major cause of
premature morbidity and mortality globally, with ische-
mic heart disease and stroke responsible for 24·4% of all
deaths in 2010 [1, 2]. About 80% of these CVD deaths
occur in low-and middle-income countries [3]. CVD
rates have decreased in developed nations due to major
public health interventions and better preventive treat-
ment, but they are a major contributor to the increasing
burden of non-communicable diseases in developing
countries [4–6]. In India, CVD already cause about 27%
of deaths, indicating a rapid pace of epidemiological
transition [7].
Modifiable CVD risk factors (including tobacco use,
physical activity levels, blood pressure [BP], blood
cholesterol, and diabetes) are common and are amen-
able to effective public health and clinical interven-
tions [8–11]. Traditionally, clinical management of
CVD risk factors has been based on directing treat-
ment at abnormal levels of individual risk factors (i.e.
treating “hypertension” or elevated cholesterol levels), how-
ever guidelines worldwide are increasingly incorporating
* Correspondence: dpraveen@georgeinstitute.org.in
1The George Institute for Global Health, Hyderabad, India
2University of New South Wales, Sydney, Australia
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Praveen et al. BMC Public Health         (2018) 18:1264 
https://doi.org/10.1186/s12889-018-6142-x
the estimation of absolute CVD risk to determine whether
preventive drugs should be initiated [12–16]. Recently in
India, the central government launched the National Pro-
gram on prevention and control of Cancer, Diabetes, Car-
diovascular diseases, and Stroke (NPCDCS). As India does
not have locally developed algorithms to predict CVD risk,
WHO/ISH risk charts for SEAR-D region (details are ex-
plained in the methodology section) are recommended for
clinical use [17]. The program advocates the use of BP low-
ering drugs in patients with intermediate CVD risk and BP
levels ≥140/90 mmHg and those with high CVD risk and
BP levels ≥130/80 mmHg [17]. NPCDCS was initiated in
2010 and is being rolled out across India in a phased man-
ner. Currently, the program has been implemented in 100
of a total 675 districts, but little is known about its adoption
and the potential consequences.
The objectives of the current analyses were to describe
the population distribution of BP and CVD risk in a
large rural Indian community, to describe current BP
treatment patterns, and to compare the efficiency of sin-
gle risk factor and absolute CVD risk approaches to BP
lowering in this setting.
Methods
The data used in these analyses were collected as the
baseline assessment of a cluster randomized trial
(SMARThealth India) evaluating an intervention aimed
at improving CVD risk management [18]. A full house-
hold survey was conducted in 54 villages in Andhra
Pradesh, India between February 2014 and May 2014.
Participant selection
A total of 18 Primary Healthcare Centers (PHCs),
broadly representative of West Godavari District of
Andhra Pradesh were selected for participation in the
SMARThealth India trial. Of the four revenue divisions
of West Godavari district, all except three PHCs
belonging to the Narsapur revenue division were se-
lected based on trial eligibility. A further three PHCs
were included from the neighboring Eluru revenue div-
ision [18]. Three villages were randomly selected from
each PHC and a census list comprising the age and sex
of all residents was enumerated from the 54 villages.
All eligible persons of age 40 years and above were
identified and interviewed after obtaining written
informed consent. If an individual was not available at
the initial visit, up to three additional visits were made
to obtain the required data.
Data collection
A questionnaire was administered to collect information
on socio-demographic variables, CVD risk factors,
known chronic conditions and current drug treatments.
Each participant had their BP recorded in the seated pos-
ition using an automated sphygmomanometer (Model
UA-767PBT-C40, A&D Medical, Tokyo, Japan) after at
least 5 min of rest. The measurement was done thrice,
with each measurement made at least 2 min apart. The
average of the last two readings was considered for the
study. Finger prick capillary blood glucose was estimated
using a point-of-care device (Abbott FreeStyle Optium,
Alameda, California, USA) with fasting status at the time
of sampling recorded.
Estimation of CVD risk
Ten year risk of fatal or non-fatal major CVD event
(myocardial infarction or stroke) was estimated using
algorithms based on the World Health Organization/
International Society for Hypertension (WHO/ISH) risk
charts [19]. These are color-coded charts tailored to 14
WHO epidemiological sub-regions, including South-East
Asian Region-D (SEAR D; includes India). The risk
charts predict the risk of CVD based on age, sex, smok-
ing status, level of blood cholesterol, BP, and absence or
presence of diabetes. There are two types of charts avail-
able - high information charts, for use when blood chol-
esterol information is available, and low information
charts in the absence of cholesterol information. As
blood cholesterol was not measured in this study, the
low information charts were used. These charts use
categories of risk factors: age (40 to 49, 50–59, 60–69,
70 years, and older), sex (male, female), smoking (no,
smoker, or ex-smoker < 12 months), systolic BP (< 129·9,
130 to 149·9, 150 to 169·9, and > 170 mmHg), and
presence of diabetes (fasting blood glucose ≥126 mg%;
non-fasting blood glucose ≥200 mg%) to estimate
10-year cardiovascular risk. The non-fasting blood glu-
cose threshold used for diagnosis of diabetes is consist-
ent with other population-based diabetes screening
programs in India [20].
To estimate the population distribution of CVD risk,
pre-treatment BP levels were imputed for all participants
reporting use of BP lowering medications. This was done
by using the method described by Wald and Law for cal-
culating the pre-treatment systolic and diastolic BP
levels, as 80% of the high-risk patients on BP lowering
treatment in the current study were on a single drug
regimen [21]. The risk charts allocate individuals into
the 5 risks groups: < 10%, 10–19%, 20–29%, 30–39%,
and ≥ 40%. Any patient with established coronary heart
disease, cerebrovascular disease, peripheral vascular
disease or with a BP > 160/100 mmHg are categorised as
high risk without the need for formal risk assessment.
The risk charts predict risk for individuals aged 40 to
79 years; for the current analyses, age was fixed at
79 years for individuals aged 79 or older.
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Estimation of treatment benefit with different strategies
for BP lowering
First, we estimated the number of events that are likely
to occur in the study population if it was fully untreated
over the next ten years. In these analyses, pre-treatment
BP levels were imputed for individuals taking BP lower-
ing treatment. As the WHO/ISH charts assign an indi-
vidual to a category of risk, rather than an integer, the
median value for each risk category was used as an indi-
cator of average risk in each category. For example, for
the category of < 10% risk the mid-point value of 5% was
used, for the category of 10–20% the mid-point value of
15% was used, and so forth. For the category of > 40%
(which included those with known CVD or BP > 160/
100), a mid-point value of 50% was used. The mid-point
value of risk for each category was then applied to the
number of individuals within that risk category, and
combining these values provided a total number across
the population.
The next step was to estimate the number of events
that would be averted under different treatment para-
digms. Numerous randomized trials have shown that BP
lowering reduces the relative risk of CVD events across
a broad range of initial BP or CVD risk levels [22–25].
We used a relative risk reduction of 15% based on recent
analyses of the Blood Pressure Lowering Treatment Tri-
alists’ Collaboration [25]. For examining risk-based treat-
ment paradigms, we only used three categories of risk:
participants with a 10-year risk of ≥30% were grouped
along with those with established CVD and BP > 160/
100 mmHg as “high risk”; participants with absolute risk
of 20–30% as “intermediate risk”, and < 20% as “low
risk”. Participants were also classified as having or not
having “hypertension” based on BP thresholds of 140/
90 mmHg. The BP lowering treatment paradigms that
were compared to an untreated population were: 1)
current practice; 2) treating people with “hypertension”
using the 140/90 mmHg threshold; 3) treatment accord-
ing to the new Indian NPCDCS guidelines (drug therapy
recommended in patients with CVD risk 20–30% and
BP levels ≥140/90 mmHg or CVD risk of ≥30% and BP
levels ≥130/80 mmHg [17]; 4) treating everyone in the
intermediate and high risk categories (regardless of BP
level); and 5) treating only those in the high risk
category (regardless of BP level).
Indicative cost-effectiveness analyses
The cost-effectiveness of each of the strategies relative
to current practice in terms of cost per disability
adjusted life years (DALYS) averted were estimated.
Costs included costs of CV medication and potential
savings associated with reduced hospitalisation from
CVD events over 10 years. Medication cost was assumed
to be 10 cents per day based on the costs of
antihypertensive medications in India [26] (for a total of
10 years in case of high risk) and cost of hospitalization
was estimated to be 200 USD for each event [27]. DALYs
were determined by dividing total burden in terms of
disability adjusted life year lost due to coronary heart
diseases with the total number of acute coronary events
per year in India based on current burden of disease
estimates [28, 29]. These were then applied to the esti-
mates of CVD events averted with each strategy.
Sensitivity analyses
Sensitivity analyses were performed with the following
differing assumptions to those made for the primary
analyses: 1) relative risk reduction of CVD events with
BP lowering drug therapy (10% and 20%); 2) estimated
pre-treatment BP levels for those already on treatment
(10 mmHg lower SBP and 5 mmHg lower DBP; and
5 mmHg lower SBP and 3 mmHg lower DBP); and 3)
average 10-year CVD risk for individuals with an esti-
mated risk in the > 40% band using the WHO/ISH
charts (40% and 60%).
Statistical analysis
Post-stratification weights were used to adjust for the
survey design and sampling methods, both at the PHC
and the village level. The PHC weight was based on the
ratio of the 24 eligible PHCs in the West Godavari
region to the sampled 18 PHCs. Village weight was the
ratio of the total number of villages in each PHC to the
sampled three villages per PHC. The final weight was
calculated as a product of the PHC weight and the
village weight. This provided appropriate standardized
estimates for the population of 24 PHCs of West Goda-
vari region and minimized any potential sampling bias.
The population distribution based on the age and sex of
the weighted sample population was similar to the popu-
lation distribution of the West Godavari district derived
from the Government of India census data [30].
Statistical analyses were carried out using statistical
package SAS 9·3 (SAS, NC, USA). The “Surveyfreq”,
“Surveymean”, and “Surveyreg” procedures were used to
include survey weights, where relevant. Overall and age
and sex stratum- specific estimates of risk factor levels
were reported. Means and proportions were presented
with 95% confidence intervals. Risk factor levels were
compared between groups using independent t-tests for
continuous variables and chi-square tests for propor-
tions. A p-value of < 0·05 was considered to indicate a
result unlikely to have been observed by chance.
Results
Participant characteristics
The eligible study population (age ≥ 40 years) from 54
villages was 74,402. Data were collected from 62,254
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(83·7%) participants; 10,332 (13·9%) were not available
for interview and 1816 (2·4%) refused participation.
Non-participants were on average younger (43·0 vs.
54·1 years, p < 0·001) and more likely to be male (51·6%
vs. 46·8%, p < 0·001) than participants. Diabetes status
was unknown in 60 individuals, thus data from 62,194
individuals (Table 1) were included in these analyses.
Classification of CVD risk
Four percent of the study population reported estab-
lished CVD. After imputing pre-treatment BP levels in
patients already on treatment, 11·8% had “hypertension”
using a BP threshold of 160/100 mmHg and 29.9% had
“hypertension” using a BP threshold of 140/90 mmHg.
The proportions having low, intermediate and high
10-year CVD risk were 76·8%, 5·3%, and 17·9%, respect-
ively. Fewer individuals than may be expected were clas-
sified at intermediate risk; this was largely a result of
those with BP > 160/100 mmHg being automatically
classified as high risk. There was substantial overlap in
systolic BP across CVD risk categories (Fig. 1).
Blood pressure management
A total of 12,230 individuals (19·6%) were taking BP low-
ering medication at the time of data collection. Imputing
pre-treatment BP levels, 47·6% of those currently treated
were classified as low risk (Fig. 2). Conversely, 4·2% and
11·8% of untreated individuals were estimated to be at
intermediate or high risk, respectively.
Comparison of treatment paradigms
If the population were completely untreated, an esti-
mated 9442 CVD events would occur over ten years.
Currently, approximately one in five individuals receive
BP lowering treatment.
Comparison of alternate strategies to current practice
Targeting all intermediate- or high-risk individuals would
result in a slightly greater proportion being treated, but
Table 1 – Characteristics of the study populationa
Overall (n = 62,194) Male (n = 29,097) Female (n = 33,097) p-values
Age (years), mean (95% CI) 54·0 (53·7–54·3) 54·7 (54·4–55·1) 53·3 (53·0–53·6) < 0·001
Female, % (95% CI) 53·2 (52·5–53·9)
Currently smoking, % (95% CI) 21·9 (20·6–23·2) 41·0 (38·5–43·4) 5·1 (4·4–5·8) < 0·001
Currently chewing tobacco, % (95% CI) 1·5 (1·2–1·8) 3·1 (2·4–3·8) 0·1 (0·0–0·1) < 0·001
Established CVD, % (95% CI) 4·0 (3·7–4·3) 5·0 (4·6–5·3) 3·2 (2·8–3·6) < 0·001
Myocardial infarction/angina, % (95% CI) 2·3 (2·0–2·6) 2·7 (2·4–3·0) 2·0 (1·7–2·3) < 0·001
Stroke, % (95% CI) 1·8 (1·6–1·9) 2·3 (2·1–2·6) 1·2 (1·0–1·5) < 0·001
Peripheral vascular diseases, % (95% CI) 0·1 (0·1–0·2) 0·2 (0·1–0·3) 0·1 (0·0–0·1) < 0·001
Self-reported diabetes, % (95% CI) 11·6 (10·6–12·6) 11·3 (10·2–12·3) 11·8 (10·8–12·9) 0·143
All diabetes, % (95% CI) 18·0 (16·8–19·2) 17·8 (16·6–18·9) 18·3 (16·9–19·6) 0·250
SBP (mmHg), mean (95% CI) 126·3 (125·2–127·3) 124·2 (123·4–125·1) 128·1 (126·8–129·4) < 0·001
DBP (mmHg), mean (95% CI) 79·8 (79·2–80·4) 79·4 (78·8–79·9) 80·3 (79·6–80·9) < 0·001
BP lowering treatment, % (95% CI) 19·6 (18·4–20·9) 16·1 (15·1–17·2) 22·7 (21·2–24·2) < 0·001
10-year adjusted cardiovascular risk, % (95% CI)b
I < 10% risk 63·9 (62·5–65·2) 63·3 (61·8–64·8) 64·4 (62·6–66·1) 0·168
II 10–20% risk 13·0 (12·5–13·5) 13·9 (13·0–14·7) 12·2 (11·7–12·6) < 0·001
III 20–30% risk 5·3 (4·9–5·6) 5·9 (5·4–6·4) 4·8 (4·5–5·0) < 0·001
IV 30–40% risk 1·2 (1·1–1·3) 1·8 (1·6–2·1) 0·6 (0·5–0·7) < 0·001
V > 40% risk 0·8 (0·8–0·9) 0·6 (0·5–0·7) 1·0 (0·9–1·2) < 0·001
VI Established CVD 4·0 (3·7–4·4) 5·0 (4·6–5·3) 3·2 (2·8–3·6) < 0·001
VII BP ≥160/100 mmHg 11·8 (11·1–12·5) 9·5 (8·9–10·1) 13·8 (12·9–14·8) < 0·001
10-year adjusted cardiovascular risk groups, % (95% CI)b
Low risk (I + II) 76·8 (75·7–78·0) 77·2 (76·1–78·4) 76·5 (75·1–78·0) 0·251
Intermediate risk (III) 5·3 (4·9–5·6) 5·9 (5·4–6·4) 4·8 (4·5–5·1) < 0·001
High risk (IV + V + VI + VII) 17·9 (16·9–18·8) 16·9 (16·1–17·7) 18·7 (17·4–20·0) 0.001
aWeighted estimates bAfter estimation of pre-treatment BP for those on BP lowering treatment
CVD cardiovascular disease, SBP systolic blood pressure, DBP diastolic blood pressure, BP blood pressure
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would almost double the number of events averted over
ten years (5·3% vs. 9·9%; Table 2). If only high-risk individ-
uals were targeted for treatment, there would be a 9% re-
duction in total population treated, but would lead to
62·7% greater number of averted events. Implementation
of NPCDCS guidelines would result in the treatment of a
similar number of individuals, but with a 77·3% increase
in the number of events averted.
Comparison of alternate strategies to ‘hypertension’ strategy
Treatment of all intermediate- and high-risk individuals
would result in 29.1% reduction in proportion of popula-
tion treated with 7.4% greater number of averted events.
Treatment as per the NPCDCS guidelines would lead to
a similar number of events averted but would require
35.5% lesser number of individuals treated. If only high
risk individuals were treated, there would be a 45.2%
Fig. 1 Frequency density of systolic blood pressure stratified by estimated 10-year CVD risk
Fig. 2 Estimated 10-year CVD risk distribution
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reduction in total population treated and 6.6% reduction
in the number of events averted.
The cost effectiveness estimates found that treatment
of all at high risk relative to current practice was cost
saving (dominant). Treatment as per the NPCDCS
guidelines (ICER = 27/DALY averted) and treatment of
all at intermediate and high risk (ICER = 73.2/DALY
averted) were each found to be highly cost effective
(Table 3). These conclusions were based on the World
Health Organization benchmarks (highly cost effective:
ICER < one time per capital gross national income
($1570); cost-effective: ICER < three times per capital
gross national income ($4710)) [31, 32].
Sensitivity analyses
Varying the major assumptions used in these analyses
resulted in minimal to modest changes to estimates of
the treated population size and numbers of events
averted, however the differences between treatment
paradigms remained broadly similar (Tables 1–6, online
Appendix).
Discussion
There are three important findings from this large
cross-sectional study. First, a substantial proportion of
this rural Indian population is at elevated risk of CVD.
Second, many low-risk individuals currently receive BP
lowering therapy, while treatment gaps among inter-
mediate- and high-risk populations remain. Third, the
widespread implementation of Indian guidelines that en-
courage an absolute risk approach to BP lowering treat-
ment is highly cost-effective and in the specific case of
treating all at high risk, cost-saving. Through this ap-
proach many more CVD events could be averted by
treating fewer individuals, as well as significant amounts
of money saved, if current practice was replaced with a
strategy that only treats individuals at high CVD risk, re-
gardless of BP level.
The finding of substantial CVD risk-factor burden in
a rural Indian population is no longer surprising and
reflects a rapid epidemiological transition that is affect-
ing disadvantaged groups in low- and middle-income
countries globally [7, 19]. The threat that CVD and
other non-communicable diseases pose is now widely
recognized with the World Health Assembly’s adoption
of Global Action Plan for Prevention and Control of
Non-communicable Diseases 2013–2020 [33]. This
includes a global “25 by 25” goal – achieving 25% rela-
tive reduction in overall mortality from CVD, cancer,
diabetes, and chronic respiratory diseases by 2025. Four
of the nine targets within the Global Action Plan dir-
ectly relate to control and management of BP related
disease – namely; reducing population intake of salt/so-
dium; reducing or containing BP; essential drug
availability; and appropriate drug therapy to prevent
heart attack and stroke. Cost-effective strategies to
identify and provide appropriate BP lowering drug
treatment to individuals are therefore crucial to achiev-
ing at least some of these targets.
The advantages of basing treatment decisions on an in-
dividual’s CVD risk, rather than using an often-arbitrarily
defined threshold level of an individual risk-factor have
been long recognized [13, 19, 25, 34]. A recent large
meta-analysis of BP lowering trials further strengthens the
rationale for taking a risk-based approach, demonstrating
similar CVD event protection regardless of initial BP level
[25]. Therefore, as expected, the greatest absolute benefits
of treatment accrued to those individuals at highest base-
line risk. Strategies for identifying and treating individuals
at high CVD risk are particularly important in low- and
middle-income countries with major resource constraints
and large under-treated populations [35]. Despite guide-
lines globally having an increased focus on absolute CVD
risk-based approaches to blood pressure control [25],
most practice appears to be entrenched on traditional par-
adigms that solely treat “hypertension”.
Our data indicate that current treatment in rural
Andhra Pradesh is primarily driven by BP level rather
than risk level, with approximately one-half of those on
treatment being low risk, and only about 45% of indi-
viduals at high risk taking BP lowering drugs. The
NPCDCS program in India, introduced in 2010, has
largely taken a risk-based approach; further implemen-
tation of these recommendations would avert more
events with the same proportion of the population
currently being treated. Approximately 1.7 million
events in individuals 40 years and above in Andhra Pra-
desh would be averted when compared to 0.9 million
events, if the NPCDCS program recommendations are
followed. Our data indicate that other risk-based ap-
proaches may be even more cost-efficient, an important
consideration if available drug resources are severely
constrained. We show that a similar number of CVD
events could be averted as with current treatment, but
with only half of the number of individuals requiring
treatment using a 10-year absolute CVD risk threshold
of 30%, this means 14 patients would require drug
treatment for ten years to avert a CV event compared
to 26 with current practice. Similar conclusions have
been reached in studies in high-income countries [36, 37],
but to the best of our knowledge this is the first-time com-
prehensive population-based data in a low- and middle-in-
come country have established the advantages of an
absolute risk approach to BP management.
The strengths of this study include collection of data on
risk factors for CVD in virtually all eligible individuals in
54 villages of a south Indian state, likely to be
generalizable to much of rural India. Robust, reproducible
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methods of data collection were used to collect these data.
However, there are also some limitations. While only 13%
of those eligible did not participate, these individuals were
on average younger and more likely to be male than study
participants. The former might have resulted in an
over-estimation of population levels of CVD risk, however
the opposite is true of the latter. The effectiveness of an
absolute-risk approach relies on accurate CVD risk-assess-
ment tools. While it has been adopted by NPCDCS, the
performance of the WHO-ISH charts has not been ad-
equately evaluated in the Indian context, and no other val-
idated tools currently exist. The use of random (rather
than fasting) blood glucose measurements (also adopted
by the regular screening processes in NPCDCS) may have
resulted in under-diagnosis of diabetes and thus under-es-
timation of the size of the high-risk population.
Study limitations
We have made several assumptions in describing the
effects of different treatment paradigms, based on
meta-analyses of relevant clinical trials [38]. However
sensitivity analyses indicate our conclusions remain
robust to varying assumptions (please see Additional file
1). It should also be noted that treatment of other CVD
risk factors was not considered in these analyses. In rela-
tion to use of other medications, recent studies in simi-
lar communities have demonstrated that even in the
context of secondary prevention, the use of statins (6%
in coronary heart disease and 1% in stroke), and anti-
platelet therapy (19·4% in coronary heart disease and
11·8% in stroke) is very low, improved coverage with
these medicines could further reduce events [39]. In the
absence of other locally developed algorithms, the
WHO/ISH risk charts for SEAR-D region were used to
define the CVD risk in this study. These risk charts are
in the process of being replaced because of concerns
about their calibration in the target population. Newer
risk charts will not likely influence the reported ranking
of the effectiveness of different interventions, but could
influence the predicted absolute numbers of events pre-
vented and the cost-effectiveness estimates. In generat-
ing cost effectiveness estimates we applied data on
India-specific average costs of pills and DALYs from the
published literature to provide an indication of the in-
vestment case for each of the strategies. Although the
estimates are crude, any error was unlikely to have
affected the reported ranking of different interventions
and findings that indicated overwhelmingly the eco-
nomic arguments for shifts in treatment paradigm away
from current practice. Finally, the study did not recruit
individuals above 85 years, which is likely to have
excluded few individuals, but a greater proportion at
higher risk.
Conclusion
An absolute risk based approach is important for prevent-
ing BP related diseases, particularly in low- and middle-in-
come countries where resource constraints are a major
barrier to CVD prevention. Guidelines are changing, but
it will take concerted effort to change the decades-old
paradigm of single-risk factor screening and management.
In this study, we present an emphatic case for doing so
based on population health outcomes and economic cri-
teria. For the risk-based approach to be maximally effect-
ive, development and use of tools that easily and
accurately predict an individual’s absolute risk of CVD is
an urgent priority. Even if such tools were available, it is
likely that healthcare providers will be slow to adopt new
paradigms of treatment in the presence of numerous
health system barriers, but unless funders and policy
makers very rapidly re-orient “hypertension” pro-
grammes to CVD risk management, the likelihood of
achieving some of the 25 × 25 targets will be signifi-
cantly compromised.
Additional file
Additional file 1: Tables S1-S6. We have made several assumptions in
describing the effects of different treatment paradigms, based on meta-
analyses of relevant clinical trials. The additional file 1 consists results of
sensitivity analyses conducted to indicate our conclusions remain robust
to varying assumptions. (DOCX 34 kb)
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